Medi-Slim Weight Loss Review: What Its GLP-1 Program Documents—and What Remains Unproven

A medication name is not the same thing as a documented treatment product. That distinction matters at Medi-Slim Weight Loss, a Las Vegas medical weight-management clinic advertising semaglutide, tirzepatide and phentermine. Its website gives prospective patients a recognizable service outline: an assessment, personalized treatment, nutritional support and progress monitoring. But it does not identify the particular semaglutide or tirzepatide products dispensed. That leaves a gap between recognizing an ingredient studied in clinical research and knowing what a patient would actually receive.

This review examines Medi-Slim’s public documentation consulted October 19, 2026, separating its commercial and care-delivery statements from independent clinical evidence. The clinic publishes useful starting prices and a substantial semaglutide inclusion list. It is less specific about pharmacy sourcing, follow-up schedules, final charges and treatment termination. The central question is therefore not whether research exists on these medicines, but how clearly Medi-Slim connects its advertised service to an identifiable product, accountable clinical care and understandable payment terms.

At a glance

Local medical weight-management practice: Medi-Slim lists a Las Vegas office at 2001 S Rainbow Boulevard, Suite 100, and says it serves the city and surrounding area.
Sources: [8] [10]
Semaglutide starting price: The medically supervised semaglutide program starts at $199 per month; the website describes administration under the skin but does not identify a brand or specific formulation.
Sources: [5]
Tirzepatide price needs a period: A limited-time offer advertises tirzepatide starting at $299 without specifying the billing or supply period. Phentermine is described as having a low monthly cost without a dollar amount.
Sources: [10]
Published semaglutide inclusions: The program lists a consultation, physical examination, medication, vitamin B12, a vitamin supplement, meal plans, a grocery list and routine monitoring. The homepage also advertises labs.
Sources: [5] [9]
Contact-form privacy limitation: Medi-Slim warns that its contact form forwards information by email rather than secure messaging and should not be used for private health information.
Sources: [6]

Start with the product, not the ingredient name

Medi-Slim explicitly lists semaglutide and tirzepatide among its prescription offerings, alongside phentermine. Its semaglutide page describes a medication administered under the skin. Those details establish that this is an advertised GLP-1 treatment service, not merely a nutrition business mentioning popular medicines. They do not establish a brand, manufacturer, presentation or dispensing source. The consulted documentation also does not resolve whether either advertised treatment uses an FDA-approved product or a compounded preparation.

The semaglutide page uses FDA-approval language, but approval belongs to a specific drug product—not a clinic or every preparation carrying an ingredient name. FDA explains that compounded drugs are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That distinction is important without being a verdict on Medi-Slim: the documents do not establish that it supplies compounded drugs, and nonapproval alone does not prove clinical inequivalence.

Before treating the clinic’s marketing as a description of a particular medicine, ask for its exact product name, formulation, presentation and dispensing pharmacy. If compounding is involved, FDA recommends compounded drugs only when an individual’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our explanation of approved medicines and compounded preparations provides context for that product-level question without assuming which category Medi-Slim uses.

What Medi-Slim’s public descriptions establish
Documented item	What it establishes	What still needs confirmation
Semaglutide under the skin	An advertised administration route	Brand, formulation, presentation and pharmacy
Semaglutide starting at $199/month	A monthly starting price	Individual final charge and later charges
Tirzepatide starting at $299	A limited-time starting offer	Billing period, supply period and final price
No monthly/yearly membership needed	No required membership is advertised	Treatment payment schedule and renewal terms
Consultations, labs and supplements	The homepage describes these as included	Specific tests, frequency and any exceptions

Sources: [10] [5] [1]

Read the starting prices as offers, not complete invoices

The clearest price is on the semaglutide program page: a medically supervised program starting at $199 per month. “Starting at” matters because it is not a universal final charge. The general presentation separately advertises semaglutide starting at $199 and tirzepatide starting at $299 as a limited-time offer. It does not attach a billing or supply period to tirzepatide. Calling that $299 a monthly price would add a condition the clinic has not documented.

Medi-Slim also advertises no hidden fees and no required monthly or yearly membership. That is useful as a statement about its business model, but it does not mean medication or clinical services stop generating recurring charges. Nor does it establish a fixed treatment price, an introductory-versus-renewal schedule or a minimum commitment. The consulted pages do not spell out automatic renewals, cancellation procedures, refund boundaries, missed-appointment charges or prepayment discounts.

A useful written quote would identify the selected medicine, covered period, included services and payment timing, then distinguish the first charge from later charges. Insurance acceptance, medication coverage, prior authorization support and any self-pay requirement are also undocumented here. These are separate questions: NIDDK notes that weight-management medicine coverage varies by plan. The lack of published insurance details should not be converted into either a promise of coverage or an assertion that Medi-Slim accepts only cash payment.

Sources: [5] [10] [2]

The semaglutide package has substance—and a lab discrepancy

Medi-Slim’s detailed semaglutide inclusion list is more informative than a price banner alone. It names a consultation, physical examination, semaglutide medication, vitamin B12, its Super Energy Supplement Vitamin, comprehensive meal plans, a grocery list and routine monitoring, including body composition. These are documented components of the advertised program. However, a list of inclusions does not establish how often each service is delivered, the quantity of medicine provided or the clinical contribution of each supplement.

The homepage additionally says the all-inclusive program offers consultations, labs and supplements without membership fees. Labs do not appear expressly in the detailed semaglutide checklist. This is a difference in scope to clarify, not evidence that testing is excluded or misleadingly billed. Prospective patients can ask which tests are included, when they are ordered, whether repeat testing is covered and whether any circumstances create separate charges. The public material does not settle those questions.

The broader weight-loss service may include dietary education and planning, plant-based supplements, appetite-suppressant medications, B12 and Lipo-B injections, nutritional counseling, health coaching and physician support. “May include” is not a promise that every patient receives every component or that all belong in the $199 starting package. The clinic also says prescribed medicines and supplements are personalized. That makes an individualized service list particularly important when comparing the advertised package with a proposed plan.

Sources: [5] [9] [11]

Clinical oversight is described more clearly than its schedule

Medi-Slim says its team is led by a physician described as board-certified in obesity and bariatric-trained, and includes a pharmacist, nurse practitioners and medical assistants. These are the clinic’s descriptions; this review did not independently verify credentials. Its semaglutide page also promises physician-led care and ongoing medical oversight. Those statements describe an intended supervisory structure, but they do not identify which professional conducts each appointment, writes each prescription or handles an urgent treatment concern.

The general service page describes a comprehensive assessment and consultation to select a suitable combination of treatments. It says the team tracks progress using a body-composition scale. This provides a concrete monitoring method rather than only a vague promise of support. Still, the documentation does not specify visit intervals, clinical review turnaround, support response times or an after-hours pathway. A body-composition measurement also does not by itself document the full content of a medical follow-up.

The semaglutide explanation mentions BMI thresholds of 30 or higher, or 27 or higher with at least one weight-related condition. That is not a complete clinic admissions protocol or an individual eligibility decision. NIDDK describes medication selection as involving health conditions, other medicines, benefits, side effects and costs. Age limits, required preliminary tests and exclusions remain unestablished here. The practical question is how Medi-Slim’s assessment translates its general description into a documented plan for the particular patient.

Sources: [10] [5] [11] [2]

Drug trials cannot supply Medi-Slim’s missing outcome data

Clinical research can establish findings about a studied medicine under specified conditions. It cannot automatically validate a clinic’s package of medication, supplements, dietary materials and monitoring. Medi-Slim’s statements about safety, effectiveness and sustainable results remain provider claims rather than independently verified clinic outcomes in this review. Its public descriptions do not supply a provider-specific outcome dataset with a defined population, follow-up period, treatment product and accounting for patients who discontinue.

STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight and a weight-related condition, without diabetes, with lifestyle intervention. SURMOUNT-1 studied subcutaneous tirzepatide in adults with obesity or overweight and a weight-related complication, also excluding diabetes. These are relevant research populations, not descriptions of everyone Medi-Slim treats. Our guides to reading STEP 1 and interpreting SURMOUNT-1 explain why study design and treatment details matter before applying findings to a commercial service.

Neither trial establishes outcomes for Medi-Slim, an unidentified compounded product, a different route or a vitamin blend. The trials also do not provide a randomized head-to-head ranking of the two drugs against each other. This leaves two distinct evidence questions: what research supports the exact proposed product, and what documentation supports the clinic’s delivery of care? A credible answer to the first cannot fill gaps in the second, and a detailed service package cannot substitute for product-specific evidence.

Sources: [5] [3] [4]

This is a documented Las Vegas service, not verified nationwide access

Medi-Slim identifies itself as a medical weight-loss practice in Las Vegas and publishes an office at 2001 S Rainbow Boulevard, Suite 100, Las Vegas, NV 89146. It says it has served Las Vegas and the surrounding area for more than 20 years. That history is a provider statement, not an independently verified operating record. More importantly for access, it does not establish treatment availability across Nevada or in other states, and telemedicine availability is not confirmed.

For entry into care, the website offers telephone scheduling and online booking. Existing patients are specifically instructed to call the office for their next visit. Published numbers distinguish appointments, at 725-977-0665, from general inquiries, at 702-258-8456. These are useful practical details because they show how to seek clarification before enrolling. Online booking alone, however, does not establish that a clinical consultation occurs online or that an appointment guarantees a prescription.

The clinic says it opens Tuesday through Saturday. Its published Tuesday-through-Friday hours are 9 a.m. to 5 p.m., with lunch closure from 1 to 2 p.m.; Saturday hours are not established by the quoted schedule. For someone planning ongoing local visits, confirming the actual appointment pattern is more useful than assuming monitoring is available whenever needed. The homepage also advertises a physician-guided phentermine program in Las Vegas, reinforcing the broader local weight-management model.

Sources: [9] [8] [10] [6]

Pharmacy and delivery responsibilities remain unresolved

The presence of a pharmacist in Medi-Slim’s advertised team does not identify the pharmacy that dispenses medication. The consulted documents name neither a dispensing nor a compounding pharmacy. They also do not explain whether patients receive medicine at the clinic, collect it elsewhere or arrange shipment. That missing operational detail matters independently of the clinical claims: patients need to know which organization supplies the prescription and who resolves labeling, packaging or fulfillment problems.

Medi-Slim’s privacy policy says it may share information with trusted partners for activities including analytics, correspondence, customer support or arranging deliveries. This is a general data-use provision, not confirmation of medication shipping. It establishes no shipping charge, dispatch window, arrival estimate or cold-chain procedure. A patient should therefore request the actual fulfillment arrangement rather than read a broad privacy clause as evidence of a mail-order treatment service.

If an injectable GLP-1 medicine is shipped, FDA explicitly recommends not using it if it arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy. FDA also reports errors measuring or administering compounded medicines, supporting the need for clear instructions from the prescriber or pharmacist rather than dose calculations from a review. These are general safeguards, not reports of an incident at Medi-Slim or evidence that its unidentified products are compounded.

Sources: [10] [7] [1]

Use the right communication channel before sharing health details

Medi-Slim offers a contact form for questions, concerns and comments, but expressly warns that submissions travel by email rather than a secure messaging system. It tells users not to transmit private health information through that form. This is a material limitation, not a minor website footnote. The form can help initiate a general inquiry, but patients should ask the office which channel it provides for medical histories, medication lists, records or treatment-specific concerns.

Optional SMS communications cover appointments and care. The notice says frequency varies, message and data rates may apply, and users can opt out by replying STOP. These messaging terms do not establish clinical response times or an urgent-care service. Likewise, opting out of texts is not documented as canceling treatment or ending payment obligations. Keeping communication preferences separate from treatment and billing arrangements avoids reading more into a short notice than it actually promises.

A focused preparation list is more useful than a general request for reassurance: ask for product identity, pharmacy, individualized charges, included tests, follow-up frequency and a secure clinical contact route. Then ask for cancellation and refund terms before paying. Our guide to what public provider documents can prove explains the boundary between an advertised feature and a verified process. Medi-Slim’s own terms similarly caution that website information should not replace individualized professional advice.

Sources: [6] [8]

Questions & answers

Is Medi-Slim’s semaglutide program exactly $199 per month?

No universal final price is documented. The program starts at $199 per month and advertises several included services without a required monthly or yearly membership. Ask what your proposed treatment costs, what period the charge covers and whether later charges differ. No membership requirement does not mean no recurring treatment payments.

Sources: [5]

Does the $299 tirzepatide offer cover a month?

The consulted offer does not say. It advertises tirzepatide starting at $299 as part of a limited-time promotion without specifying a billing or supply period. Confirm both the period and the final charge directly. The semaglutide page’s monthly wording cannot be transferred to the separate tirzepatide offer.

Sources: [10] [5]

Does Medi-Slim disclose whether its medicines are compounded?

Not in the consulted documentation. It names semaglutide and tirzepatide and describes semaglutide administration under the skin, but does not identify brands, manufacturers, presentations or a pharmacy. Ask for the exact proposed product. Neither the ingredient name nor the clinic’s FDA-approval wording resolves whether that product is approved or compounded.

Sources: [10] [5] [1]

Are laboratory tests included?

The homepage advertises labs within an all-inclusive program, while the detailed semaglutide checklist does not expressly list them. That difference needs clarification rather than an assumption of exclusion. Request the names of included tests, their expected frequency and any circumstances in which testing would be charged separately.

Sources: [9] [5]

Can patients outside Las Vegas use Medi-Slim online?

The documentation confirms a Las Vegas office and a stated service area covering the city and surroundings. It offers online booking, but that is not confirmation of telemedicine or out-of-state treatment. Before scheduling from elsewhere, ask whether the clinic can provide the consultation and continuing care where you are located.

Sources: [8] [10]

How should an existing patient arrange follow-up or send medical information?

Medi-Slim instructs existing patients to call the office for their next visit and lists 725-977-0665 for appointments. Its contact form is explicitly not secure messaging and should not carry private health information. Ask the office for its clinical communication channel and expected response time; neither is established by the general form.

Sources: [6]

Our assessment

Medi-Slim documents a recognizable local medical weight-management service, with named treatment options, a monthly semaglutide starting price, an unusually specific package checklist and practical office contact information. Its assessment and monitoring descriptions provide more substance than a medication advertisement alone. The main evidence gap is the connection between that service and the exact product patients receive: brands, formulations and pharmacy sourcing remain unidentified, while follow-up schedules and financial exit terms are incomplete. Clinical trials cannot fill those gaps or validate the clinic’s outcome claims. Before paying, obtain a written product description, individualized price and coverage period, lab inclusions, follow-up responsibilities and cancellation/refund terms. That would make the offer meaningfully easier to evaluate without assuming either clinical quality or failure from the website alone.

Visit Medi-Slim Weight Loss’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Medi-Slim Weight Loss Review: What Its GLP-1 Program Documents—and What Remains Unproven

At a glance

01Start with the product, not the ingredient name

02Read the starting prices as offers, not complete invoices

03The semaglutide package has substance—and a lab discrepancy

04Clinical oversight is described more clearly than its schedule

05Drug trials cannot supply Medi-Slim’s missing outcome data

06This is a documented Las Vegas service, not verified nationwide access

07Pharmacy and delivery responsibilities remain unresolved

08Use the right communication channel before sharing health details